We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Data Filtering Tool Helps Identify Pathogenic Mutations

By LabMedica International staff writers
Posted on 24 Jan 2016
Print article
A new tool designed to assist geneticists to differentiate between pathogenic and harmless mutations is now available on the Internet.

The fraction of the genes that codes for proteins is called the exome, and genome wide analysis has revealed that while the DNA of a patient with a monogenic disease contains about 20,000 variations, only one or two are disease causing. Thus, it is that 58% of rare variants in the protein-coding exome of the general population are located in only 2% of the genes.

To help differentiate between the many harmless variations and the few that are linked to disease, investigators at the Rockefeller Institute (New York, NY, USA) developed the gene damage index (GDI). The GDI is a data analysis tool that weighs how frequently the gene is mutated in the general population and calculates the importance of a given gene in a specific disease group, including Mendelian disorders, cancer, autism, and primary immunodeficiencies.

The investigators compared GDI with the leading gene-level approaches, genic intolerance, and de novo excess, and demonstrated that GDI performed best for the detection of false positives (i.e., removing exome variants in genes irrelevant to disease), whereas genic intolerance and de novo excess performed better for the detection of true positives (i.e., assessing de novo mutations in genes likely to be disease causing).

“To find a needle in the haystack, it helps to get rid of some of the hay,” said first author Dr. Yuval Itan, a researcher in the St. Giles Laboratory of Human Genetics of Infectious Disease at the Rockefeller Institute. “Filtering out the noise, the genes that pollute the data, is crucial. With this method, up to 60% of the irrelevant variants can be removed. The Gene Damage Index will help scientists more easily sort through the large amounts of data produced by next-generation sequencing.”

The GDI study was published in the November 3, 2015, issue of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS).

Related Links:

Rockefeller Institute


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Cancer Mutation Profiling Liquid Kit
OncoScreen Plus

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.